Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 06:10 ET | Source: Research and Markets

CD40 Targeted Therapies Opportunity Insights Report 2026-2027: Market is Emerging with Over 35 Therapies in Trials and is Driven by Technological Innovations and Global Collaborations

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has...
November 03, 2025 05:54 ET | Source: Research and Markets

Breast Cancer Antibody Drug Conjugates Market Research 2025-2030: $7 Billion Market Led by Daiichi Sankyo and AstraZeneca, with Rising Competition from Roche, Pfizer/Seagen, ADC Therapeutics

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added...
September 19, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
April 16, 2025 07:47 ET | Source: Research and Markets

KRAS Inhibitors Market Research and Forecasts 2025-2030: Lumakras, Krazati, Dupert, Anfangning Drug Sales, Patent, Price & Clinical Trials Insights

Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. ...
April 08, 2025 11:44 ET | Source: Research and Markets

LAG-3 Targeting Therapy Market & Clinical Trials Insight Report 2030: Insight on 35+ LAG-3 Targeted Therapies In Clinical Trials

Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report" report has been added to ...
January 29, 2025 06:14 ET | Source: Research and Markets

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. ...
September 06, 2024 06:48 ET | Source: Research and Markets

CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs

Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
June 20, 2024 06:59 ET | Source: Research and Markets

Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
February 01, 2024 03:16 ET | Source: Research and Markets

Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights

Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
December 18, 2023 06:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent...